Literature DB >> 14659651

In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens.

K E Bowker1, A R Noel, A P MacGowan.   

Abstract

The activity of nine peptide deformylase (PDF) inhibitors undergoing clinical evaluation were compared with co-amoxiclav, levofloxacin, moxifloxacin, erythromycin and telithromycin against a range of respiratory and skin pathogens (n=166). The PDF inhibitor showed good activity against Streptococcus pneumoniae, Moxarella catarrhalis, Group A streptococci and Staphylococcus aureus irrespective of beta-lactam or fluoroquinolone susceptibility. Against Haemophilus influenzae, MIC(90) values were generally higher. BB-88488 was the most active compound. Overall these data suggest that PDF inhibitors are an interesting new class of antimicrobial worthy of further investigation in the treatment of respiratory tract and skin infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659651     DOI: 10.1016/s0924-8579(03)00246-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors:  Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.

Authors:  Deborah Butler; Dongzhao Chen; Karen O'Dwyer; Thomas Lewandowski; Kelly Aubart; Magdalena Zalacain
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

3.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

4.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.